Magdalena Węglarz

Magdalena Węglarz

Auto-generated profile, based on publicly available information

Magdalena Węglarz

Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Colle-gium Medicum in Bydgoszcz, Nicolaus Copernicus University, 75 Ujejskiego St., 85-168 Bydgoszcz, Poland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
GGGrzegorz Grześk
Grzegorz Grześk
AWAdrianna Witczyńska
Adrianna Witczyńska
MWMagdalena Węglarz
Magdalena Węglarz
ŁWŁukasz Wołowiec
Łukasz Wołowiec
Jacek NowaczykJacek Nowaczyk
Jacek Nowaczyk
Alicja NowaczykAlicja Nowaczyk
Alicja Nowaczyk
Endogenous nitric oxide (NO)-dependent vascular relaxation plays a leading role in the homeostasis of the cardiovascular, pulmonary, and vascular systems and organs, such as the kidneys, brain, and liver. The mechanism of the intracellular action of NO in blood vessels involves the stimulation of the activity of the soluble cytosolic form of guanylyl cyclase (soluble guanylyl cyclase, sGC), increasing the level of cyclic 3′-5′—guanosine monophosphate (cGMP) in smooth muscle and subsequent vasodilation. In recent years, a new group of drugs, soluble guanylyl cyclase stimulators, has found its way into clinical practice. Based on the CHEST-1 and PATENT-1 trials, riociguat was introduced into clinical practice for treating chronic thromboembolic pulmonary hypertension (CTEPH). In January 2021, the FDA approved the use of another drug, vericiguat, for the treatment of heart failure.